Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Locus Cell Co., Ltd. (6891:TWSE), powered by AI.
Locus Cell Co., Ltd. is currently trading at $44.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Locus Cell Co., Ltd. on Alpha Lenz.
Locus Cell Co., Ltd.'s P/E ratio is 11.9.
“Locus Cell Co., Ltd. trades at a P/E of 11.9 (undervalued) with strong ROE of 45.0%. 3Y revenue CAGR of 31.0% highlights clear growth momentum.”
Ask for details →Locus Cell Co., Ltd. is a biotechnology and pharmaceutical company headquartered in New Taipei City, Taiwan. Specializing in cell therapy, the company focuses on the entrusted development and manufacturing of cell therapy-related products, serving the burgeoning life sciences tools and services sector. Founded in 2020, Locus Cell plays a role in advancing medical research and innovation in bio-therapeutic drugs, targeting critical healthcare challenges through next-generation biotechnologies. The company’s business model supports the pharmaceutical and medical research industries, collaborating on therapeutic developments that potentially address complex diseases. With a dynamic growth trajectory and increasing revenues, Locus Cell has positioned itself as a key participant in Taiwan’s biotechnology landscape, contributing to the region’s status as an innovation hub within Asia’s life sciences market. The company’s operations and output help accelerate the translation of cell-based technologies from the research stage toward clinical and commercial applications, underscoring its importance in the supply chain of cell therapy and regenerative medicine sectors.
“Locus Cell Co., Ltd. trades at a P/E of 11.9 (undervalued) with strong ROE of 45.0%. 3Y revenue CAGR of 31.0% highlights clear growth momentum.”
Ask for details →Locus Cell Co., Ltd. (ticker: 6891) is a company listed on TWSE in the Unknown sector (Unknown). Market cap is $2.3B.
The current price is 44.7 with a P/E ratio of 11.91x and P/B of 4.49x.
ROE is 45.00% and operating margin is 16.24%. Annual revenue is $1.4B.